BGM Group Ltd. (NASDAQ:BGM) Short Interest Update

BGM Group Ltd. (NASDAQ:BGM) saw a significant growth in short interest in the month of July. As of July 15th, there was short interest totaling 314,375 shares, a growth of 76.3% from the June 30th total of 178,275 shares. Based on an average daily trading volume, of 748,276 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.8% of the company’s shares are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d)” rating on shares of BGM Group in a report on Monday, April 20th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of BGM. Geode Capital Management LLC bought a new stake in BGM Group during the second quarter worth about $412,000. Mariner LLC purchased a new stake in BGM Group in the third quarter worth about $267,000. Finally, Marshall Wace LLP bought a new position in shares of BGM Group during the second quarter valued at approximately $218,000.

BGM Group Stock Up 3.8%

Shares of BGM stock opened at $0.28 on Friday. The business’s fifty day moving average is $0.33 and its 200 day moving average is $0.88. BGM Group has a twelve month low of $0.25 and a twelve month high of $11.80.

BGM Group (NASDAQ:BGM) last announced its quarterly earnings data on Tuesday, July 21st. The company reported ($0.08) EPS for the quarter. The business had revenue of $11.80 million during the quarter.

BGM Group Company Profile

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions.